Tag

COVID19

Oragenics Enters into Licensing Agreement with the National Research Council of Canada, to Pursue the Rapid Development of Next-Generation SARS-CoV-2 Vaccines

UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announced it has entered into a licensing agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue the rapid development of next-generation vaccines against the SARS-CoV-2 virus and its variants.

‘A Year of Change’: UF Reflects on COVID-19 Milestones

The University of Florida is reflecting back on the milestones made in the last year through the COVID-19 pandemic. From the initial lockdown in March 2020 to the rollout of vaccines in December, reflecting back on the year of change helps us see just how far we’ve come.

COVID-19 Testing Method Gives Results Within 1 Second

Researchers from the University of Florida and Taiwan’s National Chiao Tung University have developed a rapid and sensitive testing method for COVID-19 biomarkers. Their findings were recently published in the Journal of Vacuum Science & Technology B.

Battling COVID-19 With Smart Wearables

Dr. Swarup Bhunia, director and the Semmoto Endowed Professor at University of Florida's Electric and Computer Engineering Department, and Dr. My T. Thai, associate director and UF's Research Foundation professor at the Computer and Information Science Engineering Department, share the different Covid-19 innovations coming out of the Warren B. Nelms Institute for the Connected World​.

UF Health Study Will Examine Drugs To Treat Coronavirus UK Variant

Researchers say they aren't surprised by the coronavirus's ability to mutate, but they are working on ways to stop the spread. UF Associate Professor of Pathology David A. Ostrov's discovery about the UK variant has identified 40 candidate drugs that could serve as additional tools in the fight against COVID.